Stockscreener 앱 받기
1.84
3.16%
-0.06
시간 외 거래:
1.89
0.05
+2.72%
Nrx Pharmaceuticals Inc 주식(NRXP)의 최신 뉴스
NRx Pharmaceuticals, Inc. to Report Full Year 2025 Financial Results and Provide a Corporate Update on March 24, 2026 - Investing News Network
NRx Pharmaceuticals (NASDAQ: NRXP) Schedules March 24 Conference Call To Review 2025 Results, Clinical Progress - Digital Journal
Nrx Pharmaceuticals, Inc. (Nasdaq NRXP) to report full year 2025 financial results and provide a corporate update on March 24, 2026 - marketscreener.com
NRx Pharmaceuticals to Host Conference Call on March 24, 2026, to Discuss Financial Results and Drug Development Progress - Quiver Quantitative
NRx Pharmaceuticals, Inc. (NRXPW) Stock Price, News, Quote & History - Yahoo Finance
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) to Report Full Year 2025 Financial Results and Provide a Corporate Update on March 24, 2026 - GlobeNewswire Inc.
D Boral Capital maintains NRx Pharmaceuticals (NRXP) buy recommendation - MSN
NRx Pharmaceuticals (NASDAQ: NRXP) Receives FDA Feedback On Bioequivalence For Ketamine Product - The Globe and Mail
Analysts Conflicted on These Healthcare Names: Ionis Pharmaceuticals (IONS), Airsculpt Technologies (AIRS) and NRX Pharmaceuticals (NRXP) - The Globe and Mail
Analysts Conflicted on These Healthcare Names: Stoke Therapeutics (STOK), NRX Pharmaceuticals (NRXP) and Airsculpt Technologies (AIRS) - The Globe and Mail
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
NRx Pharmaceuticals receives FDA bioequivalence approval notice By Investing.com - Investing.com India
Joseph Michael Casper Net Worth (2026) - GuruFocus
NRx Pharmaceuticals Announces FDA Bioequivalence Determination by Office of Generic Drugs for NRx’s Preservative-Free Ketamine Application - citybiz
NRx Pharmaceuticals receives FDA bioequivalence approval notice - Investing.com
NRx Pharmaceuticals (Nasdaq:NRXP) Announces FDA Bioequivalence Determination by Office of Generic Drugs for NRx’s Preservative-Free Ketamine Application - The Manila Times
NRx Pharmaceuticals (Nasdaq:NRXP) Announces FDA - GlobeNewswire
NRx Pharmaceuticals receives FDA guidance on NRX-100 drug application By Investing.com - Investing.com South Africa
HC Wainwright & Co. Reiterates NRx Pharmaceuticals (NRXP) Buy Recommendation - MSN
Dip Buying: Is NRx Pharmaceuticals Inc Equity Warrant forming a breakout pattern - baoquankhu1.vn
NRx Pharma stock jumps after FDA signals path to NDA for ketamine depression drug - MSN
NRx Pharmaceuticals (NASDAQ: NRXP) Receives FDA Guidance Supporting NDA Review For NRX-100 - Digital Journal
NRx Pharmaceuticals' (NRXP) "Buy" Rating Reaffirmed at D. Boral Capital - MarketBeat
Why Is NRx Pharma Stock Gaining Monday?NRX Pharmaceuticals (NASDAQ:NRXP) - Benzinga
Will KETAFREE Become The First FDA-Approved Preservative-Free Ketamine Formulation? - RTTNews
NRx Pharmaceuticals (Nasdaq:NRXP) Confirms Path to New Drug Application with Real World Data and Broader Proposed Indication for NRX-100 (ketamine) Following Type C FDA Meeting - Bitget
NRx Pharmaceuticals Confirms Path to New Drug Application - citybiz
NRX Pharmaceuticals confirms path to new drug application with real world data and broader proposed indication for NRX-100 (Ketamine) following type C FDA meeting - marketscreener.com
NRx Pharmaceuticals receives FDA guidance on NRX-100 drug application - Investing.com
FDA lets ketamine depression drug seek approval without new trials - Stock Titan
NRx Pharma Stock Jumps After FDA Signals Path To NDA For Ketamine Depression Drug - Sahm
NRx Pharmaceuticals appoints Joshua C Brown chief medical innovation officer - MSN
NRx Pharmaceuticals (NASDAQ: NRXP) Appoints TMS, Neuroplasticity Researcher Joshua Brown MD, PhD, as Chief Medical Innovation Officer - Digital Journal
Bipolar Depression Market Expected to Witness Accelerated Expansion During the Forecast Period (2026-2036) Amid Advancements in Psychiatric Therapies | DelveInsight - The Malaysian Reserve
Big Money Moves: Is NRx Pharmaceuticals Inc backed by strong institutional buying2026 Technical Patterns & Weekly High Conviction Ideas - baoquankhu1.vn
NRx Pharmaceuticals Appoints Joshua C. Brown Chief Medical Innovation Officer - MyChesCo
D. Boral Capital Reaffirms "Buy" Rating for NRx Pharmaceuticals (NASDAQ:NRXP) - MarketBeat
NRx Pharmaceuticals (NASDAQ: NRXP) Subsidiary HOPE Therapeutics Opens Palm Beach Clinic for Depression and PTSD Treatment - Digital Journal
HOPE Therapeutics, an NRx Subsidiary (Nasdaq:NRXP) Announces opening of Palm Beach, FL Clinic offering One Day treatment for Depression and PTSD - The Manila Times
NRx Pharmaceuticals (NRXP) to Release Earnings on Friday - MarketBeat
HC Wainwright Has Positive Estimate for NRXP FY2026 Earnings - MarketBeat
What are NRx Pharmaceuticals Inc. Equity Warrant’s growth leversQuarterly Portfolio Summary & Low Risk Entry Point Guides - mfd.ru
H.C. Wainwright raises NRx Pharmaceuticals stock price target to $45 By Investing.com - Investing.com India
H.C. Wainwright raises NRx Pharmaceuticals stock price target to $45 - Investing.com Nigeria
Q3 EPS Forecast for NRx Pharmaceuticals Decreased by Analyst - MarketBeat
NRXP Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
NRx Pharmaceuticals (NASDAQ:NRXP) Stock Rating Upgraded by Zacks Research - MarketBeat
NRx Pharmaceuticals (NASDAQ:NRXP) Price Target Raised to $45.00 - MarketBeat
NRx Pharmaceuticals appoints Joshua Brown as chief medical officer - Investing.com
NRx Pharmaceuticals (NASDAQ: NRXP) Appoints Prof. Joshua C. Brown As Chief Medical Innovation Officer - Digital Journal
NRx Pharmaceuticals (NASDAQ: NRXP) Completes FDA Type C Meeting for NRX-100 NDA Pathway - Digital Journal
NRx Pharmaceuticals Appoints Prof. Joshua Brown MD, PhD, as Chief Medical Innovation Officer - Investing News Network
NRx Pharmaceuticals appoints Joshua Brown as chief medical officer By Investing.com - Investing.com Canada
NRx Pharmaceuticals (Nasdaq: NRXP) Appoints Prof. Joshua Brown MD, PhD, as Chief Medical Innovation Officer - marketscreener.com
What is the dividend yield of NRx Pharmaceuticals IncMarket Risk Analysis & Fast Moving Stock Trade Plans - baoquankhu1.vn
1.20%
0.06%
자본화:
|
볼륨(24시간):